Substance / Medication

Iloprost

Overview

Active Ingredient
iloprost
RxNorm CUI
40138
Labeler: BTG International IncUpdated: 2025-01-01T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
Ingegnoli Francesca, Schioppo Tommaso, Allanore Yannick et al. · Semin Arthritis Rheum · 2019
PMID: 29706243Meta-Analysis
The Efficacy and Safety of Aerosolized Iloprost in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Kuang Hongyu, Li Qiang, Yi Qijian et al. · Am J Cardiovasc Drugs · 2019
PMID: 30778875Meta-Analysis
Is iloprost effective in secondary Raynaud's phenomenon?
Lustig Nicole, Rada Gabriel · Medwave · 2015
PMID: 25826330Meta-Analysis
Inhaled iloprost for the control of acute pulmonary hypertension in children: a systematic review.
Mulligan Claire, Beghetti Maurice · Pediatr Crit Care Med · 2012
PMID: 21926655Meta-Analysis
[Randomized placebo-controlled studies of iloprost in treatment of lower limb critical ischaemia].
Kharazov A F · Angiol Sosud Khir · 2010
PMID: 21280291Meta-Analysis
Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
Pope J, Fenlon D, Thompson A et al. · Cochrane Database Syst Rev · 2000
PMID: 10796395Meta-AnalysisFull text (PMC)
Inhaled iloprost in off-pump coronary artery bypass surgery: a randomized controlled trial.
Ko Seo Hee, Shim Jae-Kwang, Song Jong-Wook et al. · Can J Anaesth · 2024
PMID: 38148468RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Iloprost (substance)
SNOMED CT
395740002
UMLS CUI
C0079594
RxNorm CUI
40138
Labeler
BTG International Inc

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.